Editas Medicine (EDIT) Q2 2024 earnings summary

Executive summary

• Achieved significant progress in Q2 2024, advancing reni-cel (gene-edited cell therapy) toward BLA and commercialization, and strengthening the in vivo gene editing pipeline.

• Completed adolescent and adult cohort enrollment in both RUBY (sickle cell disease) and EdiTHAL (beta thalassemia) trials, with robust patient dosing ongoing and positive safety and efficacy data reported.

• Shared positive clinical data at EHA 2024, showing all RUBY patients free from vaso-occlusive events and robust correction of anemia; all EdiTHAL patients transfusion-free post-treatment.

• In vivo pipeline remains on track for preclinical proof of concept by year-end, leveraging differentiated indel technology for gene upregulation.

• Strategic partnerships include collaborations with BMS, Vertex, and Vor Bio, with significant license and milestone payment potential.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $318.3 million as of June 30, 2024, down from $376.8 million at March 31, 2024.

• Net loss for Q2 2024 was $67.6 million ($0.82/share), a 68% increase compared to Q2 2023.

• Revenue for Q2 2024 was $0.5 million, down 82% year-over-year, primarily due to reduced drug supply activity with collaborators.

• Research and development expenses rose 82% year-over-year to $54.2 million in Q2 2024, driven by increased clinical and manufacturing costs for reni-cel and in vivo research.

• General and administrative expenses increased to $18.2 million in Q2 2024, mainly due to higher intellectual property and facility costs.

Outlook and guidance

• Additional clinical data from RUBY and EdiTHAL trials expected by year-end 2024.

• Preclinical in vivo proof of concept for an undisclosed indication anticipated by end of 2024.

• Cash runway expected to fund operations into 2026, including anticipated license fees and contingent payments.

• BLA package for reni-cel expected to align with industry benchmarks in terms of patient numbers and follow-up duration; timeline pending final FDA alignment.

• The company anticipates continued increases in expenses as it advances clinical development, research programs, and preclinical activities.